Topline results from an investigator-initiated trial in Brazil show that treatment with Kintor Pharmaceutical’s proxalutamide cut mortality risk by 92 percent and significantly shortened the median length of hospital stay by nine days compared with standard of care in hospitalized patients with coronavirus disease 2019.

A clinical trial of the widely used antibiotic azithromycin in hospitalized Covid-19 patients found no convincing evidence of benefit, prompting doctors to announce that they have closed that section of the trial.